Lead Product(s): HLCM051
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020
The SSC candidate of Healios (HLCM051) is in an ischemic stroke pivotal phase 2/3 trial in Japan in which it offers the potential to provide effective treatment over a much longer treatment window.